pembrolizumab
merck
['keynote 189', 'key,note,57']
keynote 189 is our soc and has shown a consistent benefit including improving os even with a crossover rate of 57%. #esmo22 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him